ProfileGDS5678 / 1446859_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 50% 49% 49% 47% 49% 51% 50% 50% 49% 49% 49% 48% 49% 49% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.2465450
GSM967853U87-EV human glioblastoma xenograft - Control 23.1709249
GSM967854U87-EV human glioblastoma xenograft - Control 33.173549
GSM967855U87-EV human glioblastoma xenograft - Control 43.0594347
GSM967856U87-EV human glioblastoma xenograft - Control 53.1118849
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.325751
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.2916950
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 33.1771150
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 43.140349
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 13.1611149
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 23.1709449
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 33.1016148
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 43.1772549
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 53.1702849